| Document |
Document Title |
|
WO/2024/111560A1 |
Provided is a compound having DDR1 inhibitory activity and represented by general formula (I), or a pharmaceutically acceptable salt or solvate thereof, and pharmaceutical use of the same.
|
|
WO/2024/112663A1 |
A deuterated compound is disclosed. A method of controlling various diseases by administration of the deuterated compound is disclosed.
|
|
WO/2024/111576A1 |
The present invention provides a human antibody or an antigen-binding portion thereof that specifically binds to human GPA33 and mouse GPA33.
|
|
WO/2024/109945A1 |
The present invention pertains to the biomedical field, and particularly relates to a series of selenium containing heterocycle compounds. The present invention also relates to a pharmaceutical composition comprising the compound, and th...
|
|
WO/2024/112287A1 |
The present invention relates to benzimidazole derivatives of formula (I) and their mPGES-1 inhibitory activity. The present invention also relates to pharmaceutical compositions containing these benzimidazole derivatives and their use i...
|
|
WO/2024/110594A1 |
The present invention generally relates to a method for enhancing the production of extracellular vesicles (EVs) from non-mammalian cells, the method comprising: (a) subjecting the cells to an acoustic and/or electromagnetic stimulation;...
|
|
WO/2024/110898A1 |
A method of treating ulcerative colitis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of the clinic...
|
|
WO/2024/086579A3 |
The technical field relates to methods for promoting gut microbiome health using low G+C Directed (LDN) analogs. More particularly, the technical field relates to methods of using LDN analogs as inhibitors of DNA Polymerase IIIC (DNA pol...
|
|
WO/2024/109479A1 |
The present invention relates to the field of biological medicines, and discloses a polypeptide and a use thereof in the preparation of an anti-fibrosis drug. The amino acid sequence of the polypeptide in the present invention is as show...
|
|
WO/2024/067891A3 |
Disclosed in the present application are the use of an Aldo-Keto reductase family 1 member C3 (AKR1C3) inhibitor in the inhibition of lipid droplet generation and the promotion of lipid droplet degradation and in the preparation of a dru...
|
|
WO/2024/111697A1 |
The present invention relates to a method for preparing a single domain VHH antibody, the method, in order to prepare a single domain VHH antibody for prevention or treatment of digestive disorder in calves, comprising, in a step for imm...
|
|
WO/2024/111982A1 |
The present invention relates to a use of a FGF5 transcript variant 2 (FGF5-v2) gene and a protein thereof for preventing or treating liver fibrosis. The FGF5-v2 fragment gene (transcript and protein expressed therefrom) according to the...
|
|
WO/2024/110614A1 |
Disclosed herein are compositions comprising a GLP-1 peptide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid for use as a medicament by oral administration.
|
|
WO/2024/112847A1 |
Compositions providing stable and protected prebiotic to provide a prebiotic delivery system to fortify feed, food or water sources for digestion activation of a dopamine precursor are disclosed. The compositions provide a protectant mat...
|
|
WO/2024/111636A1 |
The purpose of the present invention is to provide an agent for alleviating clozapine-induced sialorrhea. The agent for alleviating clozapine-induced sialorrhea according to the present invention contains, as active ingredients, dextro...
|
|
WO/2024/108691A1 |
Specifically provided are a regulatory T cell, a preparation method therefor, and an application thereof, which belong to the field of molecular immunology. By treating Treg cells in vitro by means of an adenosine 5'-monophosphate-activa...
|
|
WO/2024/110868A1 |
The present disclosure provides, among other things, treatment regimens of MAdCAM-1 antibodies for patients susceptible to or diagnosed with non-alcoholic steatohepatitis.
|
|
WO/2024/112568A1 |
A method to prevent, inhibit or treat liver disease or cholangitis in a mammal is provided comprising: administering to the mammal a composition comprising an effective amount of an antisense oligonucleotide specific for human Hippo path...
|
|
WO/2024/112270A1 |
The present invention relates to a pharmaceutical composition comprising Peritrophin and Aronia melanocarpa fruit, juice, or extract for the treatment of gastrointestinal diseases.
|
|
WO/2024/109936A1 |
The present disclosure relates to a quinoline amine compound crystal form and a preparation method therefor. Specifically, the present disclosure provides a crystal form of 8-chloro-N-(2,2-difluorobenzo[d][1,3]dioxolane-5-yl)quinolin
e-2...
|
|
WO/2024/103118A1 |
The present disclosure relates generally to gene editing systems comprising an adeno-associated virus (AAV) vector comprising a cDNA donor sequence. In particular, the gene editing systems of the present disclosure integrate the cDNA don...
|
|
WO/2024/104416A1 |
The present invention relates to an siRNA and an siRNA conjugate for inhibiting the expression of the sterol regulatory element binding protein cleavage activator protein (SCAP) gene, a pharmaceutical composition comprising same, and use...
|
|
WO/2024/104475A1 |
Disclosed in the present invention are cyclic compounds used as multi-target kinase inhibitors and a preparation method therefor. The multi-target kinase inhibitors of the present invention are represented by general formula I, wherein R...
|
|
WO/2024/108090A1 |
Provided herein are compounds and compositions thereof for modulating hepatocyte growth factors. In some embodiments, the compounds and compositions are provided for treatment of diseases, including peripheral and/or systemic inflammator...
|
|
WO/2024/104317A1 |
The present invention provides a heterocyclic compound represented by formula I, and a solvate, pharmaceutically acceptable salt, solvate of the pharmaceutically acceptable salt, or prodrug thereof. The compound has a good 15-PGDH inhibi...
|
|
WO/2024/107889A1 |
Provided herein are methods and compositions related to compositions comprising synthetic nanocarriers for treating primary biliary cholangitis (PBC).
|
|
WO/2024/105129A1 |
The present invention relates to compositions comprising lutein, non-digestible carbohydrates and at least one of casein phosphopetides or 1,3-dioleoyl-2-palmitoylglycerol.
|
|
WO/2024/104197A1 |
Provided are a peptide hydrogel and an amphiphilic peptide that can form the peptide hydrogel. The amphiphilic peptide is a salt that is acceptable in the general formula (1) Cm-IDR-Z or a physiologically tissue acceptable salt thereof, ...
|
|
WO/2024/104828A1 |
The present invention relates to an acerola fruit extract. In particular, the invention relates to biological, therapeutic effects and non-therapeutic effects of an acerola fruit extract and compositions comprising the extract.
|
|
WO/2024/067844A9 |
The present application provides a crystal A of fexuprazan hydrochloride. An X-ray powder diffraction pattern thereof has characteristic peaks at positions of 2θvalues of 9.1±0.2°, 13.7±0.2°, 14.9±0.2° and 18.3±0.2°, and has a c...
|
|
WO/2024/106846A1 |
The present invention relates to a composition comprising a Suaeda glauca extract as an active ingredient for the prevention, alleviation, or treatment of liver diseases. The Suaeda glauca extract of the present invention exhibits excell...
|
|
WO/2024/104422A1 |
Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an inflammatory bowel disease with a phosphorus-containing compound, e.g., a compound of Formula (I).
|
|
WO/2024/106529A1 |
The purpose of the present invention is to provide: a novel compound useful for promoting the breakdown of neutral fats in adipocytes; and a novel obesity treatment drug and a novel obesity-related disease treatment drug that contain the...
|
|
WO/2024/103187A1 |
A new composition of matter composed of engineered sequences for the expression of Fap2-derived polypeptides that provoke immunogenic responses against Fusobacterium spp. is provided. Antibodies and vaccines produced using such sequences...
|
|
WO/2024/103215A1 |
A pharmaceutical combination for treating fatty liver disease and use thereof. The pharmaceutical combination comprises metformin and 1,2,3,4,6-O-pentagalloylglucose. By means of the synergy between the two, the performance of glycine N-...
|
|
WO/2024/105108A1 |
The present invention provides methods for inducing a formula-fed infant's gut microbiome trajectory to converge with that of a reference gut microbiome trajectory obtained from human milk-fed infants, the methods comprising administerin...
|
|
WO/2024/108216A1 |
Compositions and methods for the management and treatment of obesity, metabolic disorders, nausea and emesis using a ODN peptides and synthetic derivatives thereof are disclosed.
|
|
WO/2024/104384A1 |
Provided herein are an indene compound, e.g., a compound of Formula (I), and a pharmaceutical composition thereof. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a fibrotic...
|
|
WO/2024/104452A1 |
A compound as shown in formula I, and a racemate, a stereoisomer, a tautomer, an isotopically labeled substance, a nitrogen oxide, a solvate, a polymorph, a metabolite, an ester, a prodrug, or a pharmaceutically acceptable salt thereof. ...
|
|
WO/2024/107434A1 |
The present invention relates to compounds of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof. Furthermore, the present invention relates to compounds of formula (I), or a salt, stereoisomer, tautomer or N-oxide thereof,...
|
|
WO/2024/105007A1 |
The present invention relates to compounds of formula (I) or a salt, stereoisomer, tautomer or N-oxide thereof. Furthermore, the present invention relates to compounds of formula (I), or a salt, stereoisomer tautomer or N-oxide thereof, ...
|
|
WO/2024/107862A1 |
The present disclosure is directed to oral dosage forms of TRβ agonists and methods of preparing the same. The disclosure provides oral dosage forms of TRβ agonists with improved stability properties that allow for storage under normal...
|
|
WO/2024/100051A1 |
The invention relates to compounds for use in the treatment of liver failure.
|
|
WO/2024/101047A1 |
According to the present invention, a graft rejection reaction is reduced, and extracellular vesicles derived from cells having physiological activity against at least one disease among kidney diseases, peripheral arterial disease (PAD),...
|
|
WO/2024/101551A1 |
Disclosed is a thermosensitive hydrogel composition for the treatment, amelioration and prevention of periodontitis and gingivitis, comprising: bakuchiol; and poloxamer as active ingredients. According to the present invention, it is eas...
|
|
WO/2024/102976A1 |
Disclosures herein are directed to methods and compositions for predicting high- and low-risk for liver fibrosis progression in patients. Based on the results achieved from the methods and compositions disclosed herein, liver disease pat...
|
|
WO/2024/100219A1 |
The present invention relates to an active ingredient consisting of the following molecules: acetic acid, butyric acid, lactic acid and propionic acid, and/or a salt and/or an ester and/or an anhydride of one or more of these molecules, ...
|
|
WO/2024/101406A1 |
The present invention provides a prophylactic and/or therapeutic agent for non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) or liver cancer, the agent containing a material for inhibiting the expression or f...
|
|
WO/2024/099229A1 |
The present invention relates to a 2-aminopyrimidine compound as represented by general formula (I) and a pharmaceutically acceptable salt, solvate, or prodrug thereof, preparation methods therefor, and a pharmaceutical composition conta...
|
|
WO/2024/101915A1 |
The present invention relates to a peptide nucleic acid complex having enhanced stability and improved inhibitory effects on a target gene, wherein the terminals of a bioactive peptide nucleic acid and a carrier peptide nucleic acid are ...
|
